Biology Reference
In-Depth Information
Selige J, Tenor H, Hatzelmann A, Dunkern T (2010) Cytokine-dependent balance of mitogenic
effects in primary human lung fibroblasts related to cyclic AMP signaling and phosphodiesterase
4 inhibition. J Cell Physiol 223(2):317-326
Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, Elliott CG, Gaine
SP, Gladwin MT, Jing ZC, Krowka MJ, Langleben D, Nakanishi N, Souza R (2009) Updated
clinical classification of pulmonary hypertension. J Am Coll Cardiol 54:S43-S54
Souness JE, Aldous D, Sargent C (2000) Immunosuppressive and anti-inflammatory effects of
cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. Immunopharmacology 47:127-162
Stavros F, Kramer WG, Wilkins MR (2010) The effects of sitaxentan on sildenafil pharmacoki-
netics and pharmacodynamics in healthy subjects. Br J Clin Pharmacol 69:23-26
Stenmark KR, Meyrick B, Galie N, Mooi WJ, McMurtry IF (2009) Animal models of pulmonary
arterial hypertension: the hope for etiological discovery and pharmacological cure. Am
J Physiol Lung Cell Mol Physiol 297:L1013-L1032
Sun CK, Lee FY, Sheu JJ, Yuen CM, Chua S, Chung SY, Chai HT, Chen YT, Kao YH, Chang LT,
Yip HK (2009a) Early combined treatment with cilostazol and bone marrow-derived endothelial
progenitor cells markedly attenuates pulmonary arterial hypertension in rats. J Pharmacol Exp
Ther 330:718-726
Sun XZ, Li ZF, Liu Y, Fang P, Li MX (2010) Inhibition of cGMP phosphodiesterase 5 suppresses
MMP2 production in pulmonary artery smooth muscles cells. Clin Exp Pharmacol Physiol 37
(3):362-367
Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER, Bedja D, Gabrielson KL,
Wang Y, Kass DA (2005) Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents
and reverses cardiac hypertrophy. Nat Med 11:214-222
Takimoto E, Koitabashi N, Hsu S, Ketner EA, Zhang M, Nagayama T, Bedja D, Gabrielson KL,
Blanton R, Siderovski DP, Mendelsohn ME, Kass DA (2009) Regulator of G protein signaling
2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5
inhibition in mice. J Clin Invest 119:408-420
Thompson WJ, Brooker G, Appleman MM (1974) Assay of cyclic nucleotide phosphodiesterases
with radioactive substrates. Methods Enzymol 38:205-212
Thompson PD, Zimet R, Forbes WP, Zhang P (2002) Meta-analysis of results from eight
randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent
claudication. Am J Cardiol 90:1314-1319
Toque HA, Teixeira CE, Priviero FB, Morganti RP, Antunes E, De Nucci G (2008) Vardenafil, but
not sildenafil or tadalafil, has calcium-channel blocking activity in rabbit isolated pulmonary
artery and human washed platelets. Br J Pharmacol 154:787-796
Trembath RC (2001) Mutations in the TGF-beta type 1 receptor, ALK1, in combined primary
pulmonary hypertension and hereditary haemorrhagic telangiectasia, implies pathway speci-
ficity. J Heart Lung Transplant 20:175
Truss MC, Stief CG, Uckert S, Becker AJ, Wefer J, Schultheiss D, Jonas U (2001) Phosphodies-
terase 1 inhibition in the treatment of lower urinary tract dysfunction: from bench to bedside.
World J Urol 19:344-350
Tsai BM, Turrentine MW, Sheridan BC, Wang M, Fiore AC, Brown JW, Meldrum DR (2006)
Differential effects of phosphodiesterase-5 inhibitors on hypoxic pulmonary vasoconstriction
and pulmonary artery cytokine expression. Ann Thorac Surg 81:272-278
Tuder RM, Groves B, Badesch DB, Voelkel NF (1994) Exuberant endothelial cell growth
and elements of inflammation are present in plexiform lesions of pulmonary hypertension.
Am J Pathol 144:275-285
Tuder RM, Abman SH, Braun T, Capron F, Stevens T, Thistlethwaite PA, Haworth SG (2009)
Development and pathology of pulmonary hypertension. J Am Coll Cardiol 54:S3-S9
Wagner RS, Smith CJ, Taylor AM, Rhoades RA (1997) Phosphodiesterase inhibition improves
agonist-induced relaxation of hypertensive pulmonary arteries. J Pharmacol Exp Ther
282:1650-1657
